Orchid Pharma (ORCHPHARMA) investor relations material

Executive summary

• Q1 FY 2027 revenue grew 15%-16% year-over-year to INR 304 crore, with gross margin improving to 33% from 30% in Q1 FY 2026.

• EBITDA rose to INR 25 crore from INR 10 crore year-over-year, reflecting operational improvements and early merger synergies.

• The merger with Dhanuka Laboratories became effective July 2026, creating an integrated anti-infective platform with expanded API and formulation capabilities.

• Unaudited standalone and consolidated financial results for Q1 FY 2027 reflect the impact of the amalgamation and recent international acquisitions.

• Positioned as a global leader in cephalosporin antibiotics, with India's only USFDA sterile cephalosporin approval and a differentiated value chain.

Financial highlights

• Q1 FY27 standalone revenue from operations was ₹30,417.13 lakhs (INR 304 crore), up from ₹26,318.58 lakhs year-over-year.

• Q1 FY27 standalone net profit was ₹1,193.72 lakhs, compared to a loss of ₹240.54 lakhs in Q1 FY26; consolidated net profit was ₹322.44 lakhs, up from a loss of ₹66.13 lakhs.

• FY26 revenue was INR 1,233 crore, down from INR 1,398 crore in FY25 due to 15%-20% declines in key products and markets.

• Standalone EBITDA for Q1 FY27 increased 178% year-over-year to ₹25 Cr, with EBITDA margin rising to 8% from 3% in Q1 FY26.

• FY26 standalone PAT was ₹35 Cr versus ₹132 Cr in FY25; EBITDA margin dropped to 8% from 13%.

Outlook and guidance

• Management expects initial benefits from merger integration projects to become visible in the next financial year.

• Demand in regulated markets is cyclical, with H2 typically stronger; management anticipates better sales in upcoming quarters but refrained from providing specific annual growth guidance.

• 7-ACA facility expected to reach 80%-100% utilization by end of first year post-commissioning, with initial output used in-house.

• FY25 and FY26 results revised to reflect the amalgamation from April 1, 2024, aligning financials with the new integrated structure.

• The company continues to monitor regulatory changes, especially regarding new Labour Codes, and will adjust provisions as needed.